Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
71-63-6
Molecular formula
C41H64O13
Molecular weight
764.9391 g/mol
Drug class
Cardiac glycosideNa+/K+-ATPase inhibitor
Mechanism of action
Inhibits Na+/K+-ATPase in cardiomyocytes, increasing intracellular sodium and reducing Na+/Ca2+ exchanger activity, thereby increasing intracellular calcium and myocardial contractility. It also increases vagal tone and slows atrioventricular conduction.
Indications / reported uses
Historical treatment of selected heart failure and supraventricular arrhythmias, including atrial fibrillation, in countries where digitoxin remains authorised; narrow therapeutic index requires concentration and clinical monitoring
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Digitoxin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Digitoxin Permitted Daily Exposure (PDE) report (the Digitoxin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Digitoxin Occupational Exposure Limit (OEL) report (the Digitoxin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.